



ISAKOS  
CONGRESS  
2025



MUNICH  
GERMANY  
June 8-11

***Bone-Patellar Tendon- Bone (BPTB)  
Allografts Are Safe And Effective  
Grafts For ACL One-Stage Revision:  
A Consecutive Series Of 38 Patients  
With At Least 2 Years Follow-Up***

**Marco Turati, MD, Monza, Italy**

**Filippo Maria Anghilieri MD, Marco Crippa MD,  
Massimiliano Piatti MD, Luca Rigamonti MD,  
Marco Bigoni, Pr MD**





# Faculty Disclosure Information

- Nothing to disclosure

## Affiliations:

- Marco Turati, IRCCS Fondazione San Gerardo, Monza, Italy
- Filippo Maria Anghilieri, S. Leopoldo Mandic Hospital, Merate, Italy
- Marco Crippa, IRCCS Fondazione San Gerardo, Monza, Italy
- Massimiliano Piatti, Policlinico S. Pietro, Bergamo, Italy
- Luca Rigamonti, Policlinico S. Pietro, Bergamo, Italy
- Marco Bigoni, University of Milano Bicocca, Italy



ISAKOS  
CONGRESS  
2025



MUNICH  
GERMANY  
June 8-11

# Introduction

- ACL rupture is one of the most common sports knee injury with rising incidence in young athletes<sup>1</sup>
- Reconstruction with autografts is first choice in active patients
- Failure rate of primary ACLR reported up to 13%<sup>2</sup>
- In young patients and in those complaining instability revision is strongly recommended
- The big issue is the graft choice in revision



ISAKOS  
CONGRESS  
2025



MUNICH  
GERMANY  
June 8-11



# Materials and methods

- Single center retrospective study in a University Hospital (IRCCS Fondazione S. Gerardo dei Tintori, Monza, Italy)
- ACL one-stage revisions with BPTB allografts
- Questionnaire via email and clinical assessment
- Patient's history and injury characteristics, Tegner activity scale, time to RTS, post-op complications, PROMs (IKDC, Lysholm, SKV)

# Materials and methods

## Inclusion criteria:

- ACL one stage revision with allograft
- BPTB allograft
- Age 18-50
- Minimum 2 years followup
- Complete medical and graft records

## Exclusion criteria:

- Multiligament (PCL, PLC, PMC, MCL)
- Allograft other than BPTB
- Skeletally immature
- F.U. shorter than 2 years
- Incomplete records




**ISAKOS**  
CONGRESS  
2025



**MUNICH**  
**GERMANY**  
June 8–11



# Results



	Total (N=38)
<b>Patients characteristics</b>	
Gender, N (%)	
Male	33 (86.8)
Female	5 (13.2)
Age at surgery (years), median (Q1-Q3)	26.1 (23.1-34.7)
Follow-up time (years), median (Q1-Q3)	5.0 (4.1-6.8)
Weight (kg), median (Q1-Q3)	74.0 (70.0-81.8)
Height (cm), median (Q1-Q3)	179.5 (172.8-183.8)
BMI (kg/m <sup>2</sup> ), median (Q1-Q3)	23.5 (21.8-24.7)
First Implant Graft, N (%)	
BPTB	28 (73.7)
semitendinosus + gracilis	3 (7.9)
semitendinosus alone	6 (15.8)
LARS	1 (2.6)
First surgery, N (%)	
Isolated ACLR	29 (76.3)
ACLR combined with meniscectomy	7 (18.5)
ACLR combined with chondral shaving	1 (2.6)
ACLR combined with medial meniscus suture	1 (2.6)

UNPUBLISHED DATA – DO NOT COPY OR DISTRIBUTE





**ISAKOS**  
CONGRESS  
2025



**MUNICH**  
**GERMANY**  
June 8-11

# Results



	Re-rupture (N=4)	No re-rupture (N=34)	p-value
<b>Patients characteristics</b>			
Gender, N (%)			0.446
<i>Male</i>	3 (75.0)	30 (88.2)	
<i>Female</i>	1 (25.0)	4 (11.8)	
Age at surgery (years), median (Q1-Q3)	23.1 (22.4-24.3)	26.8 (23.3-35.5)	0.013
Weight (kg), median (Q1-Q3)	71.0 (66.8-76.0)	75.5 (70.0-81.8)	0.493
Height (cm), median (Q1-Q3)	174.0 (166.5-179.3)	180.0 (175.0-184.8)	0.301
BMI (kg/m <sup>2</sup> ), median (Q1-Q3)	23.8 (22.9-25.1)	23.5 (21.8-24.7)	0.781
Time from injury to surgery (months), median (Q1-Q3)	12.0 (7.4-19.4)	12.8 (6.6-21.8)	0.876
<b>Donors characteristics</b>			
Gender, N (%)			0.651
<i>Male</i>	3 (75.0)	28 (82.4)	
<i>Female</i>	1 (25.0)	6 (17.6)	
Age (years), median (Q1-Q3)	41.0 (32.8-49.8)	49.0 (41.0-52.8)	0.530

UNPUBLISHED DATA – DO NOT COPY OR DISTRIBUTE



**ISAKOS**  
CONGRESS  
2025



**MUNICH**  
GERMANY  
June 8–11



# Discussion

## Why an allograft?

- To avoid further harming the knee (or contralateral) with new harvesting
- Reducing morbidity not having a donor site
- Using a new autograft is an additional disruption to a knee already undergone harvest and surgery<sup>3,4</sup>



# Discussion

## Why BPTB allograft?

- Revisions ACL often place the surgeon in front of enlarged tunnels and bone defects
- Being stored as entire extensor apparatus, BPTB allows to tailor bone plugs
- Big bone blocks are crucial to fulfil bony gaps from previous tunnels, making it easier to perform a one-stage revision, preventing from the need of an intermediate stage of bone filling (further surgery, further time to RTS)
- Soft-tissue allografts are unlikely to be predictable as a size and do not allow for large diameters

# Discussion

## Is it safe?

- From our datas 6 cases out of 38 reported surgical/post surgical complications
- All cases were trivial complications, intended not to modify the outcome
- No donor site morbidity risk and no case of infection
- 4 cases out of 38 of rerupture...statistically younger. Consider LET/ALL reconstruction



ISAKOS  
CONGRESS  
2025



MUNICH  
GERMANY  
June 8–11



# Discussion

## Is it effective?

- From our datas PROMs at median 5 years are reported to be good
- IKDC 82.8/100, SKV 77.5/100, Lysholm 85.5/100
- RTS within 9 months for 54%, within 12 months 74%
- Tegner after revision 6/10 (from 8/10)



# Conclusions

- BPTB allografts in ACL revision surgery appears to be safe and effective option, yielding to good mid-term results in RTS and function
- Great advantage in not-harming the knee with a new harvest
- Bone-blocks allow bone-to-bone healing and gaining higher diameters, avoiding 2-stage surgery
- ALL procedures should be considered in the setting of a revision, above all in younger patients



**ISAKOS**  
CONGRESS  
2025



**MUNICH**  
**GERMANY**  
June 8-11



# References

1. Maheshwer B, et al. Anterior Cruciate Ligament Tears in the Adolescent Population: Injury Demographics and Risk of Reinjury Among High School Athletes. J Pediatr Orthop 2023;43:591–7.
2. Van Eck CF et al Prospective analysis of failure rate and predictors of failure after anatomic anterior cruciate ligament reconstruction with allograft. Am J Sports Med 2012;40:800–7.
3. Bait C, et al. Italian consensus statement for the use of allografts in ACL reconstructive surgery. Knee Surg Sports Traumatol Arthrosc 2019;27:1873–81.
4. Condello V, et al. Allograft tendons are a safe and effective option for revision ACL reconstruction: a clinical review. Knee Surg Sports Traumatol Arthrosc 2019;27:1771–81.



**ISAKOS**  
CONGRESS  
2025



**MUNICH**  
**GERMANY**  
June 8–11